TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
complete
Official procurement procedure

NHS National Pharmaceuticals Dasatinib and Paliperidone Injection

Pharmaceutical products
UK
Published value
Not published
Submission deadline Not published
Lots published2
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS England: "NHS National Pharmaceuticals Dasatinib and Paliperidone Injection". Published status: complete. Published value: Value not published. 2 published lots. Submission deadline not published. See the official notice for participation instructions.
Contracting AuthorityNHS EnglandScope & CategoriesNot publishedSubmission Window
complete
No deadline published
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)Not published
Bidder Intelligence · Authority Profile: NHS England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for NHS England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Average Price Reduction
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
66.2Bids / Report
11.9% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 515 active published awards; 512 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Price reduction compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityNHS England
Procedure methodNot published
Procurement categoryNot published
Statuscomplete
Framework / DPSFramework
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published27 Apr 2023, 14:59 BST
Last source update27 Apr 2023, 14:59 BST
Recurring procurementNot published
ClassificationPharmaceutical products
Delivery area
UK
OCIDocds-h6vhtk-03981f
What is being bought
Proposed framework agreement for NHS National Generic Pharmaceuticals Dasatinib and Paliperidone Injection. Offer reference number: CM/PHG/22/5694<br/><br/><br/>Potential periods of call-offs under the framework agreement:<br/>CM/PHG/22/5694/00 - Dasatinib <br/>CESW 01/05/2023 – 30/04/2024 – (12 Months) <br/>LSNE 01/05/2023 – 30/04/2024 – (12 Months)<br/>NWLN 01/05/2023 – 30/04/2024 – (12 Months)<br/><br/>CM/PHG/22/5694/01 - Paliperidone Injection: <br/>LSNE 01/05/2023 – 31/05/2024 (13 Months) <br/>NWLN 01/05/2023 – 31/01/2025 (21 months)
What changed
From the official release history
  1. tender value changed
    27 Apr 2023, 14:59 BST
  2. Status changed to complete
    27 Apr 2023, 14:59 BST
  3. Official notice release published
    27 Apr 2023, 14:59 BST
  4. Submission deadline changed to published date
    27 Apr 2023, 14:59 BST
  5. Published value updated to £108,792,862
    17 Jan 2023, 12:40 GMT
  6. Status changed to active
    17 Jan 2023, 12:40 GMT
  7. Official notice release published
    17 Jan 2023, 12:40 GMT
  8. Submission deadline changed to 21 Feb 2023, 13:00 GMT
    17 Jan 2023, 12:40 GMT
  9. Buyer information updated
    17 Jan 2023, 12:40 GMT
Lots and requirements (2)
Published by the contracting authority
  • Lot 1 · #1
    4. Lot 1 CM/PHG/22/5694/00 Supplier offer confirmation (check box)
    cancelled
    Published valueNot published
    Invitation to offer for NHS National Generic Pharmaceuticals - Dasatinib and Paliperidone Injection<br/><br/>Period of framework agreement: The total maximum duration of the framework agreement to be no more than 21 months with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months. <br/>Potential periods of call-offs under the framework agreement:<br/><br/>CM/PHG/22/5694/00 - Dasatinib <br/>CESW - 01/05/2023 – 30/04/2024 – (12 Months) <br/>LSNE - 01/05/2023 – 30/04/2024 – (12 Months)<br/>NWLN - 01/05/2023 – 30/04/2024 – (12 Months)<br/><br/>CM/PHG/22/5694/01 - Paliperidone Injection: <br/>LSNE - 01/05/2023 – 31/05/2024 (13 Months) <br/>NWLN - 01/05/2023 – 31/01/2025 (21 months)
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
  • Lot 2 · #2
    5. Lot 2 CM/PHG/22/5694/01 Supplier offer confirmation (check box)
    cancelled
    Published valueNot published
    Invitation to offer for NHS National Generic Pharmaceuticals - Dasatinib and Paliperidone Injection<br/><br/>Period of framework agreement: The total maximum duration of the framework agreement to be no more than 21 months with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 48 months.<br/>Potential periods of call-offs under the framework agreement:<br/><br/>CM/PHG/22/5694/00 - Dasatinib<br/>CESW - 01/05/2023 – 30/04/2024 – (12 Months)<br/>LSNE - 01/05/2023 – 30/04/2024 – (12 Months)<br/>NWLN - 01/05/2023 – 30/04/2024 – (12 Months)<br/><br/>CM/PHG/22/5694/01 - Paliperidone Injection:<br/>LSNE - 01/05/2023 – 31/05/2024 (13 Months)<br/>NWLN - 01/05/2023 – 31/01/2025 (21 months)
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    27 Apr 2023, 14:59 BST
  2. Award active
    Not published · Not published
  3. Award active
    Not published · Not published
  4. Award active
    Not published · Not published
  5. Award active
    Not published · Not published
  6. Award active
    Not published · Not published
  7. Award active
    Not published · Not published
  8. Contract active
    Signed 21 Feb 2023, 00:00 GMT · £1
  9. Contract active
    Signed 21 Feb 2023, 00:00 GMT · £1
  10. Contract active
    Signed 21 Feb 2023, 00:00 GMT · £1
  11. Contract active
    Signed 21 Feb 2023, 00:00 GMT · £1
  12. Contract active
    Signed 21 Feb 2023, 00:00 GMT · £1
  13. Contract active
    Signed 21 Feb 2023, 00:00 GMT · £1
Commercial outcome and competition
Awards
Zentiva Pharma UK Ltd
Not published · Not published · active
Teva UK Limited
Not published · Not published · active
Mylan
Not published · Not published · active
Janssen-Cilag Ltd
Not published · Not published · active
Teva UK Limited
Not published · Not published · active
Mercury Pharmaceuticals Limited
Not published · Not published · active
Contracts
Lot 1-CM/PHG/22/5694/00
£1 · signed 21 Feb 2023, 00:00 GMT · active
Lot 1-CM/PHG/22/5694/00
£1 · signed 21 Feb 2023, 00:00 GMT · active
Lot 1-CM/PHG/22/5694/00
£1 · signed 21 Feb 2023, 00:00 GMT · active
CM/PHG/22/5695/01
£1 · signed 21 Feb 2023, 00:00 GMT · active
CM/PHG/22/5695/01
£1 · signed 21 Feb 2023, 00:00 GMT · active
CM/PHG/22/5695/01
£1 · signed 21 Feb 2023, 00:00 GMT · active
Bid statistics
bids: 5
bids: 5
bids: 5
bids: 5
bids: 5
bids: 5
electronicBids: 5
electronicBids: 5
electronicBids: 5
electronicBids: 5
electronicBids: 5
electronicBids: 5
Buyer and organisations in this procedure

NHS England

Contracting authority GB-FTS-67205
View buyer profile

  • NHS England
    buyer
    centralPurchasingBody

    1st Floor, Quarry House, Quarry Hill, Leeds, UKE, LS2 7UE
    sharron.giblin@nhs.net

  • Janssen-Cilag Ltd
    supplier

    High Wycombe, UK

  • Mercury Pharmaceuticals Limited
    supplier

    London, UK

  • Mylan
    supplier

    Hatfield, UK

  • Teva UK Limited
    supplier

    Castleford, UK

  • The High Court
    reviewBody

    The Strand, London, WC2A 2LL

  • Zentiva Pharma UK Ltd
    supplier

    Felstead, UK
Documents (0)
Official links; attachments are not copied
No data
No linked documents are published
Related procedures (0)
No data
No related procedures published